Literature DB >> 24507845

Current drug treatment, chronic and acute.

Peter Calverley1.   

Abstract

The appropriate management of chronic obstructive pulmonary disease (COPD) involves more than taking prescription medicines. The key components have been set out in detail in many treatment guidelines, both national and international. They include the avoidance of identified risk factors, especially tobacco smoking, and the optimization of daily physical activity. This article reviews the key components of the pharmacologic treatment of COPD, both acute and chronic, with an emphasis on those recent studies, which are likely to change practice in the next few years.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bronchodilators; COPD and exacerbations; Inhaled corticosteroids

Mesh:

Substances:

Year:  2014        PMID: 24507845     DOI: 10.1016/j.ccm.2013.09.009

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN: 0272-5231            Impact factor:   2.878


  2 in total

1.  The inhibitor of semicarbazide-sensitive amine oxidase, PXS-4728A, ameliorates key features of chronic obstructive pulmonary disease in a mouse model.

Authors:  A G Jarnicki; H Schilter; G Liu; K Wheeldon; A-T Essilfie; J S Foot; T T Yow; W Jarolimek; P M Hansbro
Journal:  Br J Pharmacol       Date:  2016-10-12       Impact factor: 8.739

2.  Therapeutic effects of LASSBio-596 in an elastase-induced mouse model of emphysema.

Authors:  Gisele A Padilha; Isabela Henriques; Miquéias Lopes-Pacheco; Soraia C Abreu; Milena V Oliveira; Marcelo M Morales; Lidia M Lima; Eliezer J Barreiro; Pedro L Silva; Debora G Xisto; Patricia R M Rocco
Journal:  Front Physiol       Date:  2015-09-30       Impact factor: 4.566

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.